The effect of a sodium glucose cotransporter 2 inhibitor (SGLT2i) in reducing heart failure hospitalization in the EMPA-REG OUTCOMES trial has raised the possibility of using these agents to treat established heart failure. We hypothesize that osmotic diuresis induced by SGLT2 inhibition, a distinctly different diuretic mechanism than that of other diuretic classes, results in greater electrolyte-free water clearance and, ultimately, in greater fluid clearance from the interstitial fluid (IF) space than from the circulation, potentially resulting in congestion relief with minimal impact on blood volume, arterial filling and organ perfusion. We utilize a mathematical model to illustrate that electrolyte-free water clearance results in a greater reduction in IF volume compared to blood volume, and that this difference may be mediated by peripheral sequestration of osmotically inactive sodium. By coupling the model with data on plasma and urinary sodium and water in healthy subjects who received either the SGLT2i dapagliflozin or loop diuretic bumetanide, we predict that dapagliflozin produces a 2-fold greater reduction in IF volume compared to blood volume, while the reduction in IF volume with bumetanide is only 78% of the reduction in blood volume. Heart failure is characterized by excess fluid accumulation, in both the vascular compartment and interstitial space, yet many heart failure patients have arterial underfilling because of low cardiac output, which may be aggravated by conventional diuretic treatment. Thus, we hypothesize that, by reducing IF volume to a greater extent than blood volume, SGLT2 inhibitors might provide better control of congestion without reducing arterial filling and perfusion.
The effect of a sodium glucose cotransporter 2 inhibitor (SGLT2i) in reducing heart failure hospitalization in the EMPA-REG OUTCOMES trial has raised the possibility of using these agents to treat established heart failure. We hypothesize that osmotic diuresis induced by SGLT2 inhibition, a distinctly different diuretic mechanism than that of other diuretic classes, results in greater electrolyte-free water clearance and, ultimately, in greater fluid clearance from the interstitial fluid (IF) space than from the circulation, potentially resulting in congestion relief with minimal impact on blood volume, arterial filling and organ perfusion. We utilize a mathematical model to illustrate that electrolyte-free water clearance results in a greater reduction in IF volume compared to blood volume, and that this difference may be mediated by peripheral sequestration of osmotically inactive sodium. By coupling the model with data on plasma and urinary sodium and water in healthy subjects who received either the SGLT2i dapagliflozin or loop diuretic bumetanide, we predict that dapagliflozin produces a 2-fold greater reduction in IF volume compared to blood volume, while the reduction in IF volume with bumetanide is only 78% of the reduction in blood volume. Heart failure is characterized by excess fluid accumulation, in both the vascular compartment and interstitial space, yet many heart failure patients have arterial underfilling because of low cardiac output, which may be aggravated by conventional diuretic treatment. Thus, we hypothesize that, by reducing IF volume to a greater extent than blood volume, SGLT2 inhibitors might provide better control of congestion without reducing arterial filling and perfusion.
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| INTRODUCTION
The EMPA-REG OUTCOME trial, which evaluated the SGLT2 inhibitor (SGLT2i) empagliflozin in patients with increased cardiovascular risk, demonstrated a large and unexpected reduction in cardiovascular mortality, heart failure hospitalization and all-cause mortality. 1, 2 More recently, the Canagliflozin Cardiovascular Assessment programme (CANVAS) showed a similar decrease in heart failure hospitalization although the rate of death from cardiovascular causes was not reduced significantly. 3 Differences in heart failure hospitalization rates were apparent early, within the first few months in both trials, suggesting that treatment may have 'rescued' individuals on the verge of heart failure. This finding was unexpected and, although hypotheses have been proposed, 2, 4 there is no consensus concerning the mechanism behind this protective effect.
SGLT2 is located predominantly in the proximal tubule (PT) of the kidney, and reabsorbs sodium (Na + ) and glucose in a 1:1 M ratio.
Thus, SGLT2 inhibition reduces not only glucose reabsorption, but PT Na + reabsorption as well. In addition, SGLT2 inhibition probably stimulates an osmotic diuresis effect, particularly in the distal tubule. This is because, except in cases of excessive plasma glucose (>~250 mg/ dL), nearly all filtered glucose is normally reabsorbed in the PT and very little is delivered distally. However, with SGLT2i, un-reabsorbed glucose flows into the distal nephron and, as water is successively reabsorbed along the nephron, glucose concentration and tubular fluid osmolality is increased, reducing the osmotic gradient between the tubular fluid and interstitium. This reduces passive reabsorption of water, particularly in the collecting duct, resulting in osmotic diuresis. Na + reabsorption may also be reduced through solvent drag.
The osmotic diuresis effect of SGLT2i is distinctly different from that of other types of diuretics. Most diuretics (thiazide, loop, potassium-sparing diuretics) act by directly reducing Na + reabsorption, and water follows passively. In contrast, the osmotic diuresis effect of SGLT2i, in addition to its direct effect on proximal glucose and sodium reabsorption, acts to reduce water reabsorption, and Na + reabsorption is reduced indirectly. Thus, SGLT2i may be expected to produce greater electrolyte-free water clearance than other Na + -driven diuretics. 5, 6 While our understanding of body fluid and sodium has focused historically on the blood and interstitial fluid (IFIF) compartments, there has been growing appreciation over the last few years of the role of peripheral tissues, in particular, the skin, muscle and the skeleton, in dynamically storing and regulating body sodium. [7] [8] [9] Titze and colleagues have shown that sodium can be stored non-osmotically, without commensurate water retention, in the skin and other tissues, probably by binding with glycosaminoglycans. They proposed that skin and other tissues act as negatively charged capacitors, trapping and releasing cations 9 and effectively mitigating excess sodium and water accumulation or loss. For interventions that affect body water and sodium levels, this mechanism may play an important role. 8, 10 Many of the signs and symptoms of heart failure are the result of fluid accumulation in the interstitium, leading to peripheral and pulmonary edema, and effective treatment aims to reduce this congestion. However, while blood volume and IF volume are both increased in heart failure, much of the excess blood is accumulated in the venous system, and relative arterial underfilling resulting from low cardiac output may be a problem in many patients with heart failure. 11, 12 Treatment with diuretics and vasodilators can reduce the effective arterial circulating volume further, limiting the effectiveness of these treatments and setting in motion maladaptive compensatory responses. [13] [14] [15] [16] We hypothesize that, as a result of osmotic diuresis and greater electrolyte-free water clearance, SGLT2i produces an unexpectedly Fasting serum samples were obtained at baseline and throughout the study for determination of sodium, potassium, chloride, calcium, magnesium, phosphorus, bicarbonate, glucose, creatinine, uric acid, blood urea nitrogen and osmolality and plasma renin activity (PRA). The urine and plasma samples were assayed at an accredited centrallLaboratory (PPD Central Laboratory, Austin, Texas). The study did not assess plasma or IF volumes. For the analyses described here, data from bumetanide or dapagliflozin administered alone for the first 7 days of the study were used. Of note, the salt tablets provided in this study to precisely control sodium intake were poorly tolerated and associated with frequent adverse events including nausea, vomiting and dizziness.
Electrolyte-free water clearance (cH 2 Oe) was calculated from urine volume (V urine ), urinary sodium (U Na ), urinary potassium (U K and serum sodium (S Na ), according to Equation (1).
Total free water clearance (FWC) was calculated from urine volume, urine osmolality (U osm ) and plasma osmolality (P osm ), according to Equation (2):
| Model
We utilized a mathematical model, as illustrated in Figure 1 , to evaluate theoretically the impact of free water clearance and osmotically inactive sodium storage on blood and IF volume, and to simulate the volume response to dapagliflozin and bumetanide. The model consists of 3 compartments: blood (plasma and red blood cells), interstitial fluid and a peripheral Na + storage compartment. The peripheral compartment is a non-fluid compartment representing the Na + stored non-osmotically in the skin, muscle and skeletal tissue.
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The model makes the following assumptions:
1. Ingested water and Na + enter the blood compartment, and excreted water and Na + exit from the blood compartment.
2. Na + and water move freely between the IF and blood compartments across Na + concentration gradients.
3. Blood and IF compartments equilibrate quickly.
4. Na + intake is constant.
5. When blood Na + concentration exceeds the normal equilibrium level, there is feedback to enhance water intake, representing the effects of vasopressin-stimulated thirst. In response to increased diuresis, the increase in water intake is constrained to be less than 50% of the increase in water excretion. The final 2 assumptions are required to be consistent with observed constant plasma Na + concentrations in the healthy volunteer study, as well as with prior knowledge of the response to loop diuretics, that is, increased water intake accounts for up to 50% of the water deficit resulting from excretion. 17 See Appendix S1 for model equations, parameters (Table S1 ) and additional explanation.
The model inputs are the time courses of water and Na + intake and excretion. Once excretion and intake are specified, the amount of Na + and water in each compartment, the concentration gradient between compartments, and the Na + and water moving between each compartment can be calculated over time.
| RESULTS
Data for urine excretion and serum concentrations of sodium and glucose, as well as for urine volume and serum potassium excretion, are summarized in Figure 2 . As shown in Figure 3A , while total FWC tended to decrease over time with both regimens, dapagliflozin increased cH 2 Oe on Day 1, and it then returned to baseline. By comparison, the effect of cH 2 Oe with bumetanide was not different than that of total FWC. The difference between FWC and cH 2 Oe with dapagliflozin is probably the result of increased glucose excretion ( Figure 2 ) and the associated osmotic diuresis effect. In other words, dapagliflozin produced a greater relative increase in water excretion than in Na + excretion compared to bumetanide. Plasma renin activity increased in the bumetanide arm but was unchanged in the dapagliflozin arm, although the difference did not reach statistical significance ( Figure 3B ).
| Theoretical effect of water and Na + excretion on blood and IF volume
Before modelling the specific effects of dapagliflozin and bumetanide-generated Na + and water excretion on blood and IF volume, we considered the following hypothetical test cases, in order to better understand the effects of water and Na + excretion separately.
3.1.1 | Case 1: Response to an increase in water excretion without an increase in Na + excretion Figure 4A shows the simulated response to an increase in urinary water excretion with no change in Na + excretion. Two subcases are shown, with and without osmotically inactive peripheral Na + storage.
When Na + is not allowed to be stored peripherally, free water excretion increases blood Na + concentration and decreases blood and IF volume acutely, but ultimately has no sustained effect on any of these variables. Essentially, all water removed is eventually replaced, and the system returns to the same steady state where it began.
However, when peripheral Na + storage is included in the model, an increase in free water clearance results in a sustained reduction in IF volume. The acute changes in blood volume and blood Na + concentration are much smaller and both eventually return to normal. This aligns with the proposed role of peripheral Na + storage as a buffer to prevent large changes in blood volume and blood pressure. 
| Case 2:
Response to an increase in Na + excretion without an increase in water excretion Figure 4B shows the opposite case, the simulated response to an increase in urinary Na + excretion with no change in water excretion.
This is a physiologically unlikely scenario, but is useful for understanding the system behavior. 3.1.3 | Case 3: Increases in both Na + and water excretion
The first 2 cases represent the extremes. Figure 4C shows the response to an increase in urinary Na + excretion with 3 different levels of increased water excretion. The orange, blue and green lines correspond to a +1, 0 and −1 L change in 24-hour cH 2 Oe. In all cases, blood volume is predicted to be reduced to a similar degree. 
| Comparison of blood and IF volume response to dapagliflozin and bumetanide
We next sought to simulate the response to dapagliflozin and bumetanide, using the clinically observed water and Na Bumetanide FIGURE 2 Observed urinary sodium excretion (A), serum sodium concentration (B), urinary glucose excretion (C), serum glucose (D), urine volume (E), and urinary potassium excretion (F) during daily dosing of dapagliflozin or bumetanide. Data are given as mean (solid lines) and 25th and 75th quartiles a decaying exponential, the shape of which was determined by leastsquared fitting to the observed 24-hour urine Na + and urine volume ( Figure 5A and 5B, Column 1). It was also necessary to account for 2 additional features of the excretion data. First, in both groups, sodium excretion on Day 0 was less than expected, given that study subjects received 10 mEq sodium tablets daily, beginning 2 days before the study began. By Day 7, sodium excretion was consistent with this sodium intake. The initial lower rate of sodium excretion is probably explained by tolerability issues and reduced absorption of the salt tablet, as diarrhea, nausea and vomiting were more common FIGURE 3 Observed mean change in electrolyte-free water clearance (cH20e) and total free water clearance (FWC) (A) and plasma renin activity (PRA) (B) following initiation of dapagliflozin or bumetanide. FWC and cH20e were not different in the bumetanide arm. In the dapagliflozin arm, cH20e was higher than FWC, which decreased over time.
Dapagliflozin tended to produce a larger initial increase and a smaller subsequent decrease in electrolyte-free water clearance than bumetanide did. Although the differences were not statistically significant, plasma renin activity tended to increase with bumetanide but not with dapagliflozin Secondly, in the bumetanide group, water excretion declined below baseline after an initial peak. It is unlikely that bumetanide directly reduces water excretion over time, but this may reflect a physiologic overcompensation in water retention. In Figure 5B , we modeled this as a gradual linear decrease in water intake after Day 1. We repeated these simulations without accounting for this effect ( Figure S3 , Appendix S1). Again, altering these assumptions produced small quantitative differences in volume changes, but did not affect the conclusions of the simulations.
We then simulated the time courses of serum Na + concentration, IF volume, blood volume, peripheral Na + storage and water intake in response to the empirically fitted changes in Na + and water excretion. As shown in Figure 5A , the model predicted that Our simulations suggest that the differential effect on electrolytefree water clearance produces a relatively greater reduction in IF volume than in blood volume with dapagliflozin compared to bumetanide. This differential effect on fluid compartments has potential therapeutic implications, particularly concerning heart failure. Heart failure is of course characterized by fluid accumulation, leading to peripheral and pulmonary edema. Managing congestion is a major goal in treating heart failure, and is achieved primarily through use of loop diuretics. It is also a major challenge, because excessive blood volume reduction can have deleterious effects, including reduced arterial filling and organ perfusion, hypotension and neurohormonal activation. [13] [14] [15] [16] Neurohormonal activation, in turn, can cause greater sodium and water retention and reduced peripheral and renal perfusion as a result of vasoconstriction. Reduced renal blood flow may lead to renal impairment and further impairment in the ability to eliminate sodium and water. It has even been postulated that the higher mortality associated with use of high-dose loop diuretic might be related to these effects; however, cause and effect has not been established and these observations could also reflect confounding because more severely ill patients require larger doses of diuretics. 19 Although changes in PRA in the current healthy volunteer study were small, the fact that PRA increased with bumetanide, but was unchanged with dapagliflozin, supports the notion that neurohormonal activation with SGLT2i is less compared with that of loop diuretics. Few other data exist concerning the neurohumoral effects of SGLT2i, and these have been collected in uncontrolled studies;
however, the available data do not show activation of the reninangiotensin system with SGLT2i which, if correct, is distinct from observations with conventional diuretics.
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If our model is correct and SGLT2i indeed produces larger reductions in IF volume relative to blood volume, they may more effectively relieve signs and symptoms of interstitial congestion, and provide some relief of elevated cardiac filling pressures, without the deleterious effects of excessive blood volume depletion, including neurohumoral activation. These effects should occur soon after initiating treatment. It is tempting to speculate that the diuretic and natriuretic action of SGLT2i is related to the prevention of heart failure hospitalization that was noted in the EMPAREG-OUTCOME (empagliflozin) and CANVAS (canagliflozin) trials, although other hypotheses have also been proposed to explain this benefit. 4 Treatment with empagliflozin and canagliflozin also significantly reduced the rate of decline in renal function, an effect that may also contribute to the protective effect of these drugs in heart failure. However, treatment with SGLT2i initially decreases in GFR, making it unlikely that renoprotection accounts for the rapid reduction in heart failure hospitalization seen with SGLT2i, although their renoprotective actions may contribute to the long-term cardiovascular benefits).
A critical component of the hypothesis of differential volume regulation proposed here is the ability of peripheral tissue to sequester Na + when excess water relative to Na + is removed and IF concentrations rise, and to release Na + when the opposite occurs. The importance of peripheral Na + storage is increasingly recognized. In separate studies by Titze et al. reductions in peripheral Na+, measured by Na-MRI, were greater with furosemide 8 than with dapagliflozin. 10 However, these studies are not directly comparable, since the first evaluated heart failure patients and the second evaluated diabetic patients, and baseline peripheral sodium was quite different between the 2 studies. In addition, the dynamics of peripheral Na + storage are incompletely understood, and there may be differences in peripheral Na + storage between healthy and diseased states. Skin sodium content has been shown to be correlated with LV hypertrophy in chronic kidney disease. 22 Further research is required to fully understand the role of peripheral Na + storage in regulating IF volume in healthy and diseased states. This study utilized data from healthy volunteers. Based on knowledge of the mechanism of action of each drug, it may be reasonable to assume that the relative difference in cH 2 Oe, and thus in relative reduction in IF volume, will be maintained in diseased states such as heart failure. However, alterations in fluid status, renal function and neurohumoral activation in diabetes and/or heart failure could impact the magnitude of the response. Studies in diabetic and heart failure patients should be undertaken to further evaluate the hypothesis presented here.
Diuretics such as bumetanide and dapagliflozin stimulate thirst, and thus, increased water intake may compensate for some of the electrolyte-free water loss. Unfortunately, changes in water intake
were not measured in this study; therefore, we cannot rule out that any excess in water excretion was compensated for by increased intake. However, this seems unlikely. Rats treated with furosemide have been shown to replace less than half of the deficit in fluid volume by increasing intake. 17 The unexpectedly low rate of sodium excretion at baseline in both study arms, as well as the decline over time in water excretion in the bumetanide arm, introduced some uncertainty into the simulations. We attempted to address this by testing alternative hypotheses to explain these data ( Figures S1-S3 ). These alternative simulations did not alter the conclusions regarding the greater relative effect of SGLT2i on IF volume compared to bumetanide.
